Open Interest and Volume Dynamics
On 20 Apr 2026, Alkem Laboratories recorded an open interest (OI) of 14,204 contracts in its derivatives, up from 12,854 contracts previously, marking an absolute increase of 1,350 contracts or 10.5%. This rise in OI is accompanied by a futures volume of 9,715 contracts, indicating robust trading activity. The combined futures and options value stands at approximately ₹9,052.4 lakhs, with futures contributing ₹8,100.8 lakhs and options an overwhelming ₹6,161.5 crores, underscoring the significant derivatives market interest in the stock.
The underlying stock price closed at ₹5,664, just 4.8% shy of its 52-week high of ₹5,933.5, demonstrating strong price momentum. The stock has gained 1.64% over the past two consecutive trading sessions and outperformed its Pharmaceuticals & Biotechnology sector by 1.58% on the day, while the broader Sensex and sector indices declined by 0.25% and 0.20% respectively. This divergence highlights Alkem’s relative strength amid a subdued market backdrop.
Market Positioning and Moving Averages
Alkem Laboratories is trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling a sustained uptrend and positive investor sentiment. The rising delivery volume, which increased by 9.39% to 85,180 shares on 17 Apr compared to the five-day average, further confirms growing investor participation and confidence in the stock’s prospects.
Liquidity remains healthy, with the stock’s average traded value supporting trade sizes up to ₹1.52 crore based on 2% of the five-day average traded value. This liquidity profile favours institutional and large retail investors seeking to build or adjust positions without significant market impact.
This week's disclosed pick, a Large Cap from NBFC, comes with precise Target Price and analysis. Check if you're positioned right for this opportunity!
- - Precise target price set
- - Weekly selection live
- - Position check opportunity
Implications of the Open Interest Surge
The 10.5% increase in open interest alongside rising volumes suggests fresh capital inflows and new positions being established rather than mere position unwinding. This pattern typically indicates that market participants are taking directional bets, likely bullish given the stock’s recent price appreciation and technical strength.
Options market data, with an options value exceeding ₹6,161 crores, points to significant hedging and speculative activity. The large notional value in options contracts may reflect strategies such as call buying or bull call spreads, which benefit from upward price movements. Meanwhile, the futures segment’s value of ₹8,100.8 lakhs confirms active participation in leveraged directional trades.
Mojo Score and Analyst Ratings
Alkem Laboratories currently holds a Mojo Score of 62.0, categorised as a 'Hold' rating, an upgrade from a previous 'Sell' rating on 10 Apr 2026. This improvement reflects better fundamentals and technical outlook, though the stock remains a mid-cap with inherent volatility. The market cap stands at ₹67,088 crore, positioning Alkem as a significant player within the Pharmaceuticals & Biotechnology sector.
Investors should note that while the stock shows positive momentum and increased investor interest, the 'Hold' grade suggests cautious optimism. The recent upgrade indicates improving confidence but also signals the need for further confirmation before committing to aggressive long positions.
Sector and Market Context
The Pharmaceuticals & Biotechnology sector has experienced mixed performance recently, with many stocks facing headwinds from regulatory scrutiny and pricing pressures. Alkem’s outperformance relative to its sector peers and the broader Sensex highlights its relative resilience and potential to capitalise on sector tailwinds such as increased domestic demand and export opportunities.
Given the stock’s proximity to its 52-week high and strong technical indicators, the surge in open interest may also reflect speculative positioning ahead of upcoming corporate announcements or sector developments. Traders should monitor derivative activity closely for signs of profit booking or further accumulation.
Alkem Laboratories Ltd or something better? Our SwitchER feature analyzes this mid-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Investor Takeaway
Alkem Laboratories’ recent open interest surge in derivatives, coupled with strong price action and improved Mojo grading, suggests a cautiously optimistic outlook. The stock’s ability to maintain gains above key moving averages and its liquidity profile make it an attractive candidate for investors seeking exposure to the Pharmaceuticals & Biotechnology sector’s growth potential.
However, the 'Hold' rating advises measured participation, with investors encouraged to monitor derivative market trends and sector developments closely. The significant options market activity may also imply increased volatility, warranting risk management strategies for those entering new positions.
Overall, the data points to a market consensus leaning towards bullishness on Alkem Laboratories, supported by fresh capital inflows and positive technical momentum. This makes it a stock to watch for both short-term traders and medium-term investors aiming to capitalise on sectoral growth and company-specific catalysts.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
